Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Size And Revenue Outlook Through 2030
The in vitro diagnostic (ivd) in cardiology and neurology market size has experienced significant expansion in recent years. It is anticipated to increase from $17.22 billion in 2025 to $18.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.7%. Historically, this growth can be attributed to the rising prevalence of cardiovascular diseases, an increasing incidence of neurological disorders, the development of hospital diagnostic infrastructure, advancements in immunoassay technologies, and enhanced clinical awareness regarding early diagnosis.
The in vitro diagnostic (ivd) in cardiology and neurology market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $25.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This anticipated growth throughout the forecast period stems from factors such as an aging global populace, a heightened need for personalized diagnostic solutions, the proliferation of point-of-care testing amenities, increasing healthcare spending in developing economies, and the wider embrace of molecular diagnostics. Key developments expected during this timeframe encompass a surging desire for early disease identification, greater uptake of point-of-care tests for cardiac and neurological conditions, the broadening scope of biomarker-driven diagnostics, an intensified emphasis on both preventive and predictive testing, and the incorporation of diagnostic panels with multiple parameters.
Get A Free Sample Report With In-Depth Market Insights:
In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth Factors Behind Sustained Expansion
The expansion of personalized medicine is anticipated to propel the growth of the in vitro diagnostic (IVD) in cardiology and neurology market moving forward. Personalized medicine defines a medical approach where healthcare decisions, practices, interventions, and treatments are customized to each patient’s unique characteristics. This approach is expanding due to factors such as advancements in genomics, a deeper understanding of disease mechanisms, patient demand for tailored treatments, and regulatory support. In cardiology and neurology, in vitro diagnostic (IVD) tests are crucial to personalized medicine, as they provide essential information about an individual’s genetic makeup and disease status, thereby guiding customized treatment plans for enhanced efficacy and reduced risks. For instance, in February 2024, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization. This figure represents an increase from six approvals in 2022, with the 2023 approvals also covering seven oncology therapies and three treatments for various other conditions. Thus, the growing number of personalized medicines is fueling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.
In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segment Analysis Spotlighting Growth Areas
The in vitro diagnostic (ivd) in cardiology and neurology market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users
Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services
In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Industry Trends Fueling Future Revenue Growth
Leading companies in the in vitro diagnostic (IVD) cardiology and neurology market are developing AI-driven integrated epigenetic engines for early disease detection and risk assessment. These AI-powered integrated epigenetic engines leverage machine-learning models and advanced biomarker analysis techniques to enhance sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, thereby addressing critical drivers of disease progression. For instance, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, launched PrecisionCHD, an AI-based blood test, specifically designed for the early detection of coronary heart disease (CHD). Utilizing the company’s integrated epigenetic-genetic engine, this test evaluates CHD risk and aims to prevent and detect the most common form of cardiovascular disease. The new test combines epigenetic and genetic biomarkers with machine-learning algorithms, offering over 75% sensitivity for both men and women. It links a patient’s biomarker profile to modifiable risk factors, which are major contributors to CHD, including smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD represents a non-invasive alternative to exercise stress tests or angiograms, with blood samples drawn conveniently in-office or at home.
In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience
View The Full In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report:
In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Geographic Spread And Regional Opportunities
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
